[Video] Podcast: Dietary Supplements – Navigating the Regulatory Maze – Diagnosing Health Care

The U.S. Food and Drug Administration’s (FDA’s) broad definition of “misbranding” has created some industry confusion, while the Federal Trade Commission’s (FTC’s) updates to its Health Products Compliance Guidance have done the same. In light of these recent actions, what challenges are dietary supplement manufacturers now facing? On this episode, Epstein Becker Green attorneys Jack Wenik, Teddy McCormick, Zach Taylor, and Tracey Gonzalez discuss recent updates to the FDA and FTC guidelines…
By: Epstein Becker & Green
Previous Story

Q&A: Cisco CIO sees AI embedded in every product and process

Next Story

Roundup Users With Lymphoma May Qualify to File a Lawsuit Following Verdicts Against Bayer, Monsanto